281 reports of this reaction
2.5% of all DEUTETRABENAZINE reports
#10 most reported adverse reaction
INSOMNIA is the #10 most commonly reported adverse reaction for DEUTETRABENAZINE, manufactured by Teva Neuroscience, Inc.. There are 281 FDA adverse event reports linking DEUTETRABENAZINE to INSOMNIA. This represents approximately 2.5% of all 11,218 adverse event reports for this drug.
Patients taking DEUTETRABENAZINE who experience insomnia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INSOMNIA is a less commonly reported adverse event for DEUTETRABENAZINE, but still significant enough to appear in the safety profile.
In addition to insomnia, the following adverse reactions have been reported for DEUTETRABENAZINE:
The following drugs have also been linked to insomnia in FDA adverse event reports:
INSOMNIA has been reported as an adverse event in 281 FDA reports for DEUTETRABENAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INSOMNIA accounts for approximately 2.5% of all adverse event reports for DEUTETRABENAZINE, making it a notable side effect.
If you experience insomnia while taking DEUTETRABENAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.